Regeneron Pharmaceuticals Inc (REGN)

388.49
21.87 5.97
NASDAQ : Health Care
Prev Close 366.62
Open 368.51
Day Low/High 368.30 / 393.50
52 Wk Low/High 329.09 / 605.93
Volume 2.18M
Avg Volume 879.80K
Exchange NASDAQ
Shares Outstanding 106.29M
Market Cap 39.48B
EPS 6.20
P/E Ratio 48.23
Div & Yield N.A. (N.A)

Latest News

Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection

Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection

Monthly dosing schedule now approved in both United States and European Union

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

Cramer: Retail Rally Shows the Perils of Being Too Negative

Cramer: Retail Rally Shows the Perils of Being Too Negative

There's a forest fire in the sector.

Regeneron Is Ready to Rally

Regeneron Is Ready to Rally

An upside breakout appears on the horizon.

Regeneron, Sanofi Score Eczema Drug Approval

Regeneron, Sanofi Score Eczema Drug Approval

Regeneron and Sanofi will launch Dupixent with a gross sticker price of $37,000 per year, before insurance discounts and rebates.

European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details

European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details

European stocks drifted lower Monday following a holiday-thinned trading session in Asia as investors prepare for key inflation and private sector activity data later in the week.

European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade

European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade

European stocks are expected to open mixed Monday following a holiday-thinned trading session in Asia as investors prepare for key inflation and private sector activity data later in the week.

Dow, S&P 500 Decline as Health Care Losses Counter Gains

Dow, S&P 500 Decline as Health Care Losses Counter Gains

Wall Street ends a jampacked week little changed as a selloff in health care stocks counters broad gains elsewhere.

Broad Gains Overshadow Health Care Losses to Boost Wall Street

Broad Gains Overshadow Health Care Losses to Boost Wall Street

Stocks rise on Friday even as a selloff in health care extends into its second day.

Stocks Creep Lower as Health Care Selloff Extends Into Day 2

Stocks Creep Lower as Health Care Selloff Extends Into Day 2

Stocks creep lower on Friday as a selloff in health care extends into its second day.

Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate

Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate

Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?

Teen Scientist Researches New Approach To Neurological Damage; Wins Regeneron Science Talent Search 2017

Teen Scientist Researches New Approach To Neurological Damage; Wins Regeneron Science Talent Search 2017

Indrani Das of New Jersey Wins $250,000 Top Award in Nation's Oldest and Most Prestigious High School Science and Mathematics Competition

Teen Scientist Researches New Approach To Neurological Damage; Wins Regeneron Science Talent Search 2017

Teen Scientist Researches New Approach To Neurological Damage; Wins Regeneron Science Talent Search 2017

Indrani Das of New Jersey Wins $250,000 Top Award in Nation's Oldest and Most Prestigious High School Science and Mathematics Competition

Regeneron Could Generate More Upside

Regeneron Could Generate More Upside

Dips in the pharma name have been bought, a sign of demand that presents a relatively low-risk buying opportunity.

Regeneron Is Ready to Reanimate: Watch for a Breakout

Regeneron Is Ready to Reanimate: Watch for a Breakout

This stock is testing resistance and could push back up to last year's highs.

Regeneron Could Run Higher: Must-See Chart

Regeneron Could Run Higher: Must-See Chart

Shares of biotech giant Regeneron broke out on Thursday and are setting up well for a fresh rally leg.

Don't Give the Fed Credit for This Bull: Cramer's 'Mad Money' Recap (Thursday 3/9/17)

Don't Give the Fed Credit for This Bull: Cramer's 'Mad Money' Recap (Thursday 3/9/17)

Big market gains were the result of great companies, CEOs and the people behind them -- not just the Fed, says Jim Cramer.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Amgen: Clinical Trials Set Stage for Further Upside

Amgen: Clinical Trials Set Stage for Further Upside

This biotech name shows no sign of slowing down.

PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round

PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round

Jim Cramer is bullish on PaylPal, CH Robinson Worldwide, Texas Instruments and NXP Semiconductors.

Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)

Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)

Jim Cramer highlight's Buffett's confidence in American businesses and stocks, and his critique of high fees charged by money managers.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.